Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.
  Stock to be Quoted Under Ticker Symbol CLRB Beginning February 12, 2014 MADISON, Wis., February 11, 2014,  – Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents for the detection and treatment of cancer, announced that, effective today, its corporate name
View HTML
Toggle Summary Novelos Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
  MADISON, Wis. (February 10, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents to detect, treat and monitor a broad spectrum of cancers, today announced that Dr. Simon Pedder, acting president and CEO of Novelos, will present at the 16th Annual
View HTML
Toggle Summary Novelos Therapeutics Announces Closing of $4.0 million Private Placement
  MADISON, Wis. (February 07, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, is pleased to announce that it has closed the previously disclosed non-brokered private placement of two-year, 8% convertible
View HTML
Toggle Summary Novelos Therapeutics Announces Definitive Agreements to Raise $4.0 million in Private Placement of Convertible Debentures and Warrants
Proceeds Enable Initiation of Phase II Trial of 124I-CLR1404 in Glioma in First Quarter 2014 MADISON, Wis. (February 06, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, today announced it has entered into
View HTML
Toggle Summary Novelos Therapeutics Announces a Restructuring of its Board of Directors and Additional Changes to its Management Team
Novelos Therapeutics Announces a Restructuring of its Board of Directors and Additional Changes to its Management Team Board Appoints Paul Berns as New Independent Director and Reduces Board from Nine to Five Directors Company to Relocate Executive Offices, Close Newton Office and Centralize
View HTML
Toggle Summary Novelos Appoints Industry Veteran to Lead Strategic Realignment
Novelos Appoints Industry Veteran to Lead Strategic Realignment MADISON, Wisc. (October 9, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT) announced that the Board of Directors, on October 4, 2013, appointed Dr. Simon Pedder as Acting Chief Executive Officer and elected him a Director, replacing
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION
NOVELOS THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION MADISON, Wisc. (July 29, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, the company’s President and CEO and a
View HTML
Toggle Summary NOVELOS THERAPEUTICS PROVIDES PRODUCT PIPELINE UPDATE
NOVELOS THERAPEUTICS PROVIDES PRODUCT PIPELINE UPDATE To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 Evaluating I-131-CLR1404 (HOT) Potential Phase 2 Indications and Trial Designs To File CLR1502 (GLOW2) IND for Intraoperative Tumor Margin Illumination by End
View HTML
Toggle Summary NOVELOS THERAPEUTICS CLOSES $5.5 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS CLOSES $5.5 MILLION PUBLIC OFFERING MADISON, Wisc. (February 21, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a public offering of 11,000,000 units at
View HTML
Toggle Summary NOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING MADISON, Wisc. (February 13, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at
View HTML